Liver X receptor agonists have been combined with other antitumor agents with promising activity in preclinical studies of melanoma (vemurafenib, dacarbazine [DTIC], anti‐CTLA‐4 antibody) and pancreatic cancer (gemcitabine) [24, 44]. Here, CTLA4 is linked to familial pancreatic carcinoma.